Dermatitis Drugs Market Size, Share and Industry Analysis by Drug Class (Calcineurin Inhibitors, PDE4 Inhibitors, Corticosteroids, Biologics & Others), By Disease Indication (Atopic Dermatitis, Contact Dermatitis & Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy & Online Pharmacy), and Regional Forecast 2019-2026

Table of Content:

1.       Introduction

1.1.     Research Scope

1.2.     Market Segmentation

1.3.     Research Methodology

1.4.     Definitions and Assumptions

2.       Executive Summary

3.       Market Dynamics

3.1.     Market Drivers

3.2.     Market Restraints

3.3.     Market Opportunities

4.       Key Insights

4.1.     Prevalence of majordermatitis types by key countries, 2018

4.2.     Recent industrydevelopments such as mergers & acquisitions

4.3.     Pipeline analysis

4.4.     Patent landscape

4.5.     Reimbursement scenario bykey countries

4.6.     Regulatory scenario for keycountries

5.       Global Dermatitis DrugsMarket Analysis, Insights and Forecast, 2014-2025

5.1.     Key Findings / Summary

5.2.     Market Analysis, Insightsand Forecast – By Drug Class

5.2.1.  Calcineurin Inhibitors

5.2.2.  PDE4 Inhibitors

5.2.3.  Corticosteroids

5.2.4.  Biologics

5.2.5.  Others

5.3.     Market Analysis, Insightsand Forecast – By Disease Indication

5.3.1.  Atopic Dermatitis

5.3.2.  Contact Dermatitis

5.3.3.  Others

5.4.     Market Analysis, Insightsand Forecast – By Distribution Channel

5.4.1.  Hospital Pharmacy

5.4.2.  Retail Pharmacy

5.4.3.  Online Pharmacy

5.5.     Market Analysis, Insightsand Forecast – By Country

5.5.1.  North America

5.5.2.  Europe

5.5.3.  Asia pacific

5.5.4.  Rest of World

6.       North America DermatitisDrugs Market Analysis, Insights and Forecast, 2014-2025

6.1.     Key Findings / Summary

6.2.     Market Analysis – By DrugClass

6.2.1.  Calcineurin Inhibitors

6.2.2.  PDE4 Inhibitors

6.2.3.  Corticosteroids

6.2.4.  Biologics

6.2.5.  Others

6.3.     Market Analysis – ByDisease Indication

6.3.1.  Atopic Dermatitis

6.3.2.  Contact Dermatitis

6.3.3.  Others

6.4.     Market Analysis – ByDistribution Channel

6.4.1.  Hospital Pharmacy

6.4.2.  Retail Pharmacy

6.4.3.  Online Pharmacy

6.5.     Market Analysis – ByCountry

6.5.1.  U.S.

6.5.2.  Canada

7.       Europe Dermatitis DrugsMarket Analysis, Insights and Forecast, 2014-2025

7.1.     Key Findings / Summary

7.2.     Market Analysis – By Drug Class

7.2.1.  Calcineurin Inhibitors

7.2.2.  PDE4 Inhibitors

7.2.3.  Corticosteroids

7.2.4.  Biologics

7.2.5.  Others

7.3.     Market Analysis – ByDisease Indication

7.3.1.  Atopic Dermatitis

7.3.2.  Contact Dermatitis

7.3.3.  Others

7.4.     Market Analysis – ByDistribution Channel

7.4.1.  Hospital Pharmacy

7.4.2.  Retail Pharmacy

7.4.3.  Online Pharmacy

7.5.     Market Analysis – ByCountry

7.5.1.  U.K.

7.5.2.  Germany

7.5.3.  France

7.5.4.  Spain

7.5.5.  Italy

7.5.6.  Scandinavia

7.5.7.  Rest of Europe

8.       Asia pacific DermatitisDrugs Market Analysis, Insights and Forecast, 2014-2025

8.1.     Key Findings / Summary

8.2.     Market Analysis – By DrugClass

8.2.1.  Calcineurin Inhibitors

8.2.2.  PDE4 Inhibitors

8.2.3.  Corticosteroids

8.2.4.  Biologics

8.2.5.  Others

8.3.     Market Analysis – ByDisease Indication

8.3.1.  Atopic Dermatitis

8.3.2.  Contact Dermatitis

8.3.3.  Others

8.4.     Market Analysis – ByDistribution Channel

8.4.1.  Hospital Pharmacy

8.4.2.  Retail Pharmacy

8.4.3.  Online Pharmacy

8.5.     Market Analysis – ByCountry

8.5.1.  Japan

8.5.2.  China

8.5.3.  India

8.5.4.  Australia

8.5.5.  Southeast Asia

8.5.6.  Rest of Asia Pacific

9.       Rest of World DermatitisDrugs Market Analysis, Insights and Forecast, 2014-2025

9.1.     Key Findings / Summary

9.2.     Market Analysis – By DrugClass

9.2.1.  Calcineurin Inhibitors

9.2.2.  PDE4 Inhibitors

9.2.3.  Corticosteroids

9.2.4.  Biologics

9.2.5.  Others

9.3.     Market Analysis – ByDisease Indication

9.3.1.  Atopic Dermatitis

9.3.2.  Contact Dermatitis

9.3.3.  Others

9.4.     Market Analysis – ByDistribution Channel

9.4.1.  Hospital Pharmacy

9.4.2.  Retail Pharmacy

9.4.3.  Online Pharmacy

9.5.     Market Analysis – ByCountry

10.    Competitive Analysis

10.1. Key Industry Developments

10.2. Global Market ShareAnalysis (2017)

10.3. Competition Dashboard

10.4. Comparative Analysis –Major Players

10.5. Company Profiles (Overview,Products & services, SWOT analysis, Recent developments, strategies,financials (based on availability))

10.5.1.      Valeant Pharmaceuticals

10.5.2.      Astellas Pharma US, Inc.

10.5.3.      Pfizer, Inc.

10.5.4.      Mylan

10.5.5.      Bayer AG

10.5.6.      Allergan

10.5.7.      LEO Pharma

10.5.8.      Regeneron Pharmaceuticals,Inc.

10.5.9.      Anacor Pharmaceuticals,Inc.

11.    Strategic Recommendations